Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/ HER2-negative breast cancer-the evaluating treatment with neoadjuvant abraxane (ETNA) trial a randomized phase 3 clinical trial

  1. Gianni, L.
  2. Mansutti, M.
  3. Anton, A.
  4. Calvo, L.
  5. Bisagni, G.
  6. Bermejo, B.
  7. Semiglazov, V.
  8. Thill, M.
  9. Chacon, J.I.
  10. Chan, A.
  11. Morales, S.
  12. Alvarez, I.
  13. Plazaola, A.
  14. Zambetti, M.
  15. Redfern, A.D.
  16. Dittrich, C.
  17. Dent, R.A.
  18. Magazzu, D.
  19. De Fato, R.
  20. Valagussa, P.
  21. Tusquets, I.
Aldizkaria:
JAMA Oncology

ISSN: 2374-2445,  2374-2437

Argitalpen urtea: 2018

Alea: 4

Zenbakia: 3

Orrialdeak: 302-308

Mota: Artikulua

DOI: 10.1001/JAMAONCOL.2017.4612 GOOGLE SCHOLAR lock_openSarbide irekia editor

Objetivos de desarrollo sostenible

Datuen iturria: Scopus